DK2328893T3 - Triazolforbindelser som modulerer hsp90 aktivitet - Google Patents

Triazolforbindelser som modulerer hsp90 aktivitet

Info

Publication number
DK2328893T3
DK2328893T3 DK09791292T DK09791292T DK2328893T3 DK 2328893 T3 DK2328893 T3 DK 2328893T3 DK 09791292 T DK09791292 T DK 09791292T DK 09791292 T DK09791292 T DK 09791292T DK 2328893 T3 DK2328893 T3 DK 2328893T3
Authority
DK
Denmark
Prior art keywords
hsp90 activity
compounds modulating
triazolic compounds
modulating hsp90
triazolic
Prior art date
Application number
DK09791292T
Other languages
English (en)
Inventor
Weiwen Ying
Dinesh U Chimmanamada
Joseph A Burlison
Shijie Zhang
Minghu Song
Junghyun Chae
Original Assignee
Synta Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synta Pharmaceuticals Corp filed Critical Synta Pharmaceuticals Corp
Application granted granted Critical
Publication of DK2328893T3 publication Critical patent/DK2328893T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/101,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK09791292T 2008-08-08 2009-08-07 Triazolforbindelser som modulerer hsp90 aktivitet DK2328893T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18839708P 2008-08-08 2008-08-08
PCT/US2009/053157 WO2010017479A1 (en) 2008-08-08 2009-08-07 Triazole compounds that modulate hsp90 activity

Publications (1)

Publication Number Publication Date
DK2328893T3 true DK2328893T3 (da) 2013-06-17

Family

ID=41172462

Family Applications (1)

Application Number Title Priority Date Filing Date
DK09791292T DK2328893T3 (da) 2008-08-08 2009-08-07 Triazolforbindelser som modulerer hsp90 aktivitet

Country Status (7)

Country Link
US (1) US9126953B2 (da)
EP (1) EP2328893B1 (da)
DK (1) DK2328893T3 (da)
ES (1) ES2415234T3 (da)
PL (1) PL2328893T3 (da)
PT (1) PT2328893E (da)
WO (1) WO2010017479A1 (da)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5178515B2 (ja) 2005-08-12 2013-04-10 シンタ ファーマシューティカルズ コーポレーション Hsp90活性を調節するピラゾール化合物
US20070250391A1 (en) * 2006-04-05 2007-10-25 Prade Hendrik D Merchandising system and method for food and non-food items for a meal kit
TW200800260A (en) 2006-05-25 2008-01-01 Synta Pharmaceuticals Corp Method for treating proliferative disorders associated with protooncogene products
US8318790B2 (en) 2006-05-25 2012-11-27 Synta Pharmaceuticals Corp. Triazole compounds that modulate HSP90 activity
AU2007267859B2 (en) 2006-05-25 2012-04-12 Synta Pharmaceuticals Corp. Triazole compounds that modulate Hsp90 activity
CA2653327A1 (en) * 2006-05-25 2007-12-06 Synta Pharmaceuticals Corp. Compounds that modulate hsp90 activity and methods for identifying same
CA2653336C (en) 2006-05-25 2014-10-28 Synta Pharmaceuticals Corp. Method for treating non-hodgkin's lymphoma
EP3231442B1 (en) 2006-06-23 2019-12-25 ADC Therapeutics SA Polynucleotides and polypeptide sequences involved in cancer
DK2118077T3 (da) * 2007-02-08 2015-03-09 Synta Pharmaceuticals Corp Triazolforbindelser der modulerer hsp90-aktivitet
WO2009139916A1 (en) * 2008-05-16 2009-11-19 Synta Pharmaceuticals Corp. Tricyclic triazole compounds that modulate hsp90 activity
US8450500B2 (en) 2008-06-04 2013-05-28 Synta Pharmaceuticals Corp. Pyrrole compounds that modulate HSP90 activity
US8648071B2 (en) 2008-06-27 2014-02-11 Synta Pharmaceuticals Corp. Hydrazonamide compounds that modulate Hsp90 activity
US8106083B2 (en) 2008-08-08 2012-01-31 Synta Pharmaceuticals Corp. Triazole compounds that modulate HSP90 activity
CN102245773B (zh) 2008-11-03 2014-08-27 阿莱斯亚生物疗法股份有限公司 特异性地阻滞肿瘤抗原的生物活性的抗体
US9205086B2 (en) 2010-04-19 2015-12-08 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a Hsp90 inhibitory compounds and a EGFR inhibitor
JP2014501232A (ja) 2010-12-20 2014-01-20 シグマ−タウ・リサーチ・スウィッツァーランド・ソシエテ・アノニム 抗腫瘍活性を有するアリールトリアゾール化合物
BR112013025198A2 (pt) 2011-03-31 2018-12-04 Alethia Biotherapeutics Inc. anticorpos contra antígeno 1 associado a rim e fragmentos de ligação a antígeno do mesmo
AU2012280931A1 (en) 2011-07-07 2014-02-27 Synta Pharmaceuticals Corp. Treating cancer with HSP90 inhibitory compounds
CN102391260B (zh) * 2011-09-29 2014-12-10 上海交通大学 3-甲酮-6-取代-苯并呋喃类化合物及其制备方法和用途
WO2013067165A1 (en) 2011-11-02 2013-05-10 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitors with platinum-containing agents
AU2012332421A1 (en) 2011-11-02 2014-06-05 Synta Pharmaceuticals Corp. Cancer therapy using a combination of Hsp90 inhibitors with topoisomerase I inhibitors
WO2013074594A1 (en) 2011-11-14 2013-05-23 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitors with braf inhibitors
KR102102239B1 (ko) 2012-01-09 2020-04-21 에이디씨 테라퓨틱스 에스에이 유방암을 치료하기 위한 방법
WO2015066053A2 (en) * 2013-10-28 2015-05-07 Synta Pharmaceuticals Corp. Targeted therapeutics
CN104447658A (zh) * 2014-12-04 2015-03-25 杭州杜易科技有限公司 一种卤代4-色满酮衍生物的制备方法
US10767164B2 (en) 2017-03-30 2020-09-08 The Research Foundation For The State University Of New York Microenvironments for self-assembly of islet organoids from stem cells differentiation
US11724997B2 (en) 2018-03-01 2023-08-15 Annapurna Bio, Inc. Compounds and compositions for treating conditions associated with APJ receptor activity

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ME01498B (me) * 2004-11-18 2014-04-20 Synta Pharmaceuticals Corp Jedinjenja triazola koja modulišu aktivnost hsp90
JP5178515B2 (ja) * 2005-08-12 2013-04-10 シンタ ファーマシューティカルズ コーポレーション Hsp90活性を調節するピラゾール化合物
EP1951679B1 (en) * 2005-08-18 2015-02-18 Synta Pharmaceuticals Corp. Imidazole compounds that modulate hsp90 activity
WO2007094819A2 (en) 2005-08-18 2007-08-23 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
EP2038262B1 (en) * 2006-05-25 2014-11-12 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
TW200800260A (en) * 2006-05-25 2008-01-01 Synta Pharmaceuticals Corp Method for treating proliferative disorders associated with protooncogene products
CA2653327A1 (en) * 2006-05-25 2007-12-06 Synta Pharmaceuticals Corp. Compounds that modulate hsp90 activity and methods for identifying same
US20080125587A1 (en) * 2006-05-25 2008-05-29 Chimmanamada Dinesh U Synthesis of triazole compounds that modulate HSP90 activity
US8318790B2 (en) * 2006-05-25 2012-11-27 Synta Pharmaceuticals Corp. Triazole compounds that modulate HSP90 activity
AU2007267859B2 (en) * 2006-05-25 2012-04-12 Synta Pharmaceuticals Corp. Triazole compounds that modulate Hsp90 activity
CA2653336C (en) * 2006-05-25 2014-10-28 Synta Pharmaceuticals Corp. Method for treating non-hodgkin's lymphoma
AU2007284537B2 (en) 2006-08-17 2012-04-12 Synta Pharmaceuticals Corp. Triazole compounds that modulate HSP90 activity
US20110046125A1 (en) * 2006-10-19 2011-02-24 Synta Pharmaceuticals Corp. Method for treating infections
WO2008057246A2 (en) * 2006-10-26 2008-05-15 Synta Pharmaceuticals Corp. Method for treating inflammatory disorders
DK2118077T3 (da) * 2007-02-08 2015-03-09 Synta Pharmaceuticals Corp Triazolforbindelser der modulerer hsp90-aktivitet
WO2008112199A1 (en) * 2007-03-12 2008-09-18 Synta Pharmaceuticals Corp. Method for inhibiting topoisomerase ii
ES2395114T3 (es) * 2007-03-27 2013-02-08 Synta Pharmaceuticals Corporation Derivados de triazinona y de diazinona útiles como inhibidores de Hsp90
WO2008153730A2 (en) * 2007-05-25 2008-12-18 Synta Pharmaceuticals Corp. Method for treating proliferative disorders associated with mutations in c-met
BRPI0815116A2 (pt) * 2007-08-13 2015-01-27 Synta Pharmaceuticals Corp Compostos de triazol que modulam a atividade da hsp90
WO2009139916A1 (en) * 2008-05-16 2009-11-19 Synta Pharmaceuticals Corp. Tricyclic triazole compounds that modulate hsp90 activity
US8450500B2 (en) * 2008-06-04 2013-05-28 Synta Pharmaceuticals Corp. Pyrrole compounds that modulate HSP90 activity
US8648071B2 (en) * 2008-06-27 2014-02-11 Synta Pharmaceuticals Corp. Hydrazonamide compounds that modulate Hsp90 activity
US8106083B2 (en) * 2008-08-08 2012-01-31 Synta Pharmaceuticals Corp. Triazole compounds that modulate HSP90 activity
PL2490688T3 (pl) * 2009-10-19 2015-03-31 Synta Pharmaceuticals Corp Terapia skojarzona przeciw nowotworom z użyciem związków hamujących HSP90
US20130156755A1 (en) * 2010-04-19 2013-06-20 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a hsp90 inhibitory compounds and a vegf inhibitor
US9205086B2 (en) * 2010-04-19 2015-12-08 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a Hsp90 inhibitory compounds and a EGFR inhibitor
US20130172333A1 (en) * 2010-05-20 2013-07-04 Synta Pharmaceuticals Corp. Formulation and dosing of hsp90 inhibitory compounds
EP2575810A1 (en) * 2010-05-24 2013-04-10 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a hsp90 inhibitory compound and a topoisomerase ii inhibitor
WO2012026931A1 (en) * 2010-08-25 2012-03-01 Synta Pharmaceuticals Corp. Method of synthesizing substituted 2-alkyl phenols
WO2012037072A1 (en) * 2010-09-13 2012-03-22 Synta Pharmaceuticals Corporation Hsp90 inhibitors for treating non-small cell lung cancers in wild-type egfr and/or kras patients
EP2648708A2 (en) * 2010-12-08 2013-10-16 Synta Pharmaceuticals Corp. Combination for breast cancer therapy with hsp90 inhibitory compounds
WO2012096919A1 (en) * 2011-01-11 2012-07-19 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitory compounds with proteasome inhibitors
EP2678013A1 (en) * 2011-02-23 2014-01-01 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitory compounds with radiotherapy
WO2012141796A2 (en) * 2011-02-24 2012-10-18 Synta Pharmaceuticals Corp. Prostate cancer therapy with hsp90 inhibitory compounds
US20140045908A1 (en) * 2011-02-25 2014-02-13 Synta Pharmaceuticals Corp. Hsp90 inhibitory compounds in treating jak/stat signaling-mediated cancers
US8628752B2 (en) * 2011-10-28 2014-01-14 Synta Pharmaceuticals Corp. Methods of identifying HSP90 inhibitors with less ocular toxicity

Also Published As

Publication number Publication date
WO2010017479A1 (en) 2010-02-11
PL2328893T3 (pl) 2013-09-30
EP2328893B1 (en) 2013-03-20
US20110224206A1 (en) 2011-09-15
ES2415234T3 (es) 2013-07-24
EP2328893A1 (en) 2011-06-08
US9126953B2 (en) 2015-09-08
PT2328893E (pt) 2013-06-27

Similar Documents

Publication Publication Date Title
DK2328893T3 (da) Triazolforbindelser som modulerer hsp90 aktivitet
DK2035396T3 (da) Triazolforbindelser der modulerer hsp90-aktivitet
CY2019011I2 (el) C7-φθορο υποκατεστημενες ενωσεις τετρακυκλινης
DK2364293T3 (da) Hidtil ukendte pyrazol-4-N-alkoxycarboxamider som mikrobiocider
NO2021006I1 (no) Quofenix, delafloksacin
DK2369934T3 (da) Spiroheterocykliske n-oxypiperidiner som pesticider
BRPI0917369A2 (pt) Compostos inseticidas
BRPI0918500A2 (pt) compostos inseticidas
BRPI0917188A2 (pt) Compostos inseticidas
DK2288375T3 (da) Pegylerede insulin-lispro-forbindelser
BRPI0920707A2 (pt) compostos
DK2242759T3 (da) Forbindelser
DK2291368T3 (da) Substitueret gamma-lactam som terapeutisk middel
DK2144897T3 (da) 8-Oxy-quinolinderivater som bradykinin B2-receptormodulatorer
BRPI1007310A2 (pt) Compostos inseticidas.
BRPI0819093A2 (pt) compostos moduladores de sirtuína
BRPI0909656A2 (pt) Microencapsulamento
ITBO20080040A1 (it) Tagliaerba.
BRPI0918430A2 (pt) 4-fenil-1h-pirazóis inseticidas.
BRPI0908269A2 (pt) aplicador
DK2612845T3 (da) Aromatisk forbindelse som indeholder specifik forgrening
BRPI0922464A2 (pt) Combinações de compostos ativos
DK2401256T3 (da) Forbindelser som bradykinin-B1-antagonister.
DK2297162T3 (da) Forbindelser
DK2373652T3 (da) Substituerede piperidin-spiro-pyrrolidinon- og piperidinon-forbindelser anvendt som h3-modulatorer